sarepta therapeutics fda - Search News

Order byBest matchMost fresh

News

Sarepta stock extends decline

· 13h · on MSN

Sarepta stock extends decline as company declines FDA call to withdraw drug

Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and Drug Administration request to stop selling a drug tied to three deaths.

Continue reading

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

· 12h · on MSN

Sarepta extends losses premarket after refusing FDA’s halt request

FDA Shuts Down Sarepta Gene Therapy Trials

BioPharma Dive · 2h

FDA asks Sarepta to stop shipping Duchenne gene therapy

The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still walk. A pause on shipments to older, non-ambulatory patients remains in place.

Continue reading

Fierce Pharma · 8h

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market

Sarepta tells FDA it won’t halt shipments despite patient deaths

2h

Sarepta under pressure: FDA requests halt of Elevidys shipments

Sarepta Therapeutics (SRPT) stock is in focus after the US Food and Drug Administration (FDA) asked the company to halt ...

9h

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

STAT4hOpinion

The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

10h

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys

FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results